Egyptian perspective of research in sickle cell disease

Fatma Soliman Elsayed Ebeid

doi:10.5281/zenodo.15831942

Authors

Fatma Soliman Elsayed Ebeid Pediatric Hematology Oncology and BMT, Ain Shams University Research Institute, Cairo, Egypt https://orcid.org/0000-0002-3761-6373

DOI:

https://doi.org/10.5281/zenodo.15831942

Keywords:

Sickle cell disease, Clinical research, Randomized controlled trial, SCD

Abstract

Objective: Hemoglobinopathies including sickle cell disease (SCD) are prevalent inherited disorders in most Arab countries including Egypt. The heterogeneous distribution with variable prevalence in Egypt may be due to the historical trade exchange, high prevalence of consanguineous marriage, and internal migration.

Materials and methods: The literature search was conducted in the PubMed MEDLINE database including articles indexed as of 15^th Apr 2024, if they involved patients with SCD in Egypt.

Results: In this work, we presented the research originated from Egypt addressing the SCD which includes case reports, original articles, and randomized clinical trials, and highlighted how this research efforts open the doors for understanding the prevalence and pathophysiology, improvement of the diagnostic methods, and the breakthrough treatment.

Conclusions: Although scanty research was carried out in the nineteenth century and the first decade of the twentieth century, SCD became an area of focus for research in 2010. The standard of care and the infrastructure improved with the involvement of several centres in multicenter international clinical trials.

References

GBD 2021 Sickle Cell Disease Collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599.

Herrick JB, Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Internal Med. 1910;6:517–21.

El-Hazmi MA, Al-Hazmi AM, Warsy AS. Sickle cell disease in Middle East Arab countries. Indian J Med Res. 2011;134(5):597-610.

Chakravorty S, Williams TN Sickle cell disease: a neglected chronic disease of increasing global health importance Archives of Disease in Childhood 2015;100:48-53.

Aygun B, Odame IA. global perspective on sickle cell disease. Pediatr Blood Cancer 2012;59(2):386-90.

ASH Research Collaborative. https://www.ashresearchcollaborative.org/s/sickle-cell-disease-community. Accessed on 16 March 2024.

Inusa BPD, Colombatti R, Rees DC, Heeney MM, Hoppe CC, Ogutu B, et al. Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study. J Clin Med. 2019;8(11):2009.

Abbasy AS; Case Report: Sickle Cell Anemia; First Case Reported from Egypt. Blood 1951;6(6):555–8.

Salah M, Massoud M, Saleh WA. Effects of maternal sickle cell haemoglobinopathy on pregnancy. J Egypt Public Health Assoc. 1991;66(3-4):373-86.

el-Hazmi MA, Warsy AS, Bashir N, Beshlawi A, Hussain IR, Temtamy S, et al. Haplotypes of the beta-globin gene as prognostic factors in sickle-cell disease. East Mediterr Health J. 1999;5(6):1154-8.

El-Beshlawy A, Youssry I. Prevention of hemoglobinopathies in Egypt. Hemoglobin. 2009;33:S14-20.

Timmann C, Meyer CG. King Tutankhamun's family and demise. JAMA. 2010;303(24):2473; author reply 2473-5.

Timmann C, Meyer CG. Malaria, mummies, mutations: Tutankhamun's archaeological autopsy. Trop Med Int Health. 2010;15(11):1278-80.

Pays JF. Toutankhamon et sicklanémie (Tutankhamun and sickle-cell anaemia). Bull Soc Pathol Exot. 2010;103(5):346-7.

El-Beshlawy A, Abd El Raouf E, Mostafa F, Talaat M, Isma'eel H, Aoun E, et al. Diastolic dysfunction and pulmonary hypertension in sickle cell anemia: is there a role for L-carnitine treatment? Acta Haematol. 2006;115(1-2):91-6.

ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32(8):601-5.

Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-66.

Khamees I, Ata F, Choudry H, Soliman AT, De Sanctis V, Yassin MA. Manifestations of HbSE sickle cell disease: a systematic review. J Transl Med. 2021;19(1):262.

Amer YS, Sabr Y, ElGohary GM, Altaki AM, Khojah OT, El-Malky A, et al. Quality assessment of evidence-based clinical practice guidelines for the management of pregnant women with sickle cell disease using the AGREE II instrument: a systematic review. BMC Pregnancy Childbirth. 2020;20(1):595.

Martí-Carvajal A, Abd El Aziz MA, Martí-Amarista C, Solà I. Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review. Clin Adv Hematol Oncol. 2019;17(4):234-43.

Badawy SM, Cronin RM, Hankins J, Crosby L, DeBaun M, Thompson AA, et al. Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review. J Med Internet Res. 2018;20(7):e10940.

Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia a molecular disease. Science. 1949;110(2865):543-8.

Ata A EL-H. Sickle cell anaemia; with a case report. J Egypt Med Assoc. 1957;40(11):815-30.

Awny AY, Kamel K, Hoerman K. Investigations of hemoglobin variants. 1. Sickle-cell anemia; the importance of a battery of tests for its diagnosis, with a case report. J Egypt Med Assoc. 1960;43:89-95.

Rahman AM. Blood dyscrasias and central retinal vein occlusion. Bull Ophthalmol Soc Egypt. 1968;61(65):187-95

Kamel K. Hemoglobin variants in U.A.R. J Egypt Public Health Assoc. 1968;43:Suppl:111-7

Emarah MH. Ocular manifestations of sickle-cell haemoglobin C disease, report of a case. Bull Ophthalmol Soc Egypt. 1969;62(66):421-8

el-Sabbagh AM, Kamel M. Avascular necrosis of temporomandibular joint in sickle cell disease. Clin Rheumatol. 1989;8(3):393-7

el Sayed HL, Tawfik ZM. Red cell profile in normal and sickle cell diseased children. J Egypt Soc Parasitol. 1994;24(1):147-54.

Kandeel AY, Zimmerman RA, Ohene-Frempong K. Comparison of magnetic resonance angiography and conventional angiography in sickle cell disease: clinical significance and reliability. Neuroradiology. 1996;38(5):409-16.

Soliman AT, Bererhi H, Darwish A, Alzalabani MM, Wali Y, Ansari B. Decreased bone mineral density in prepubertal children with sickle cell disease: correlation with growth parameters, degree of siderosis and secretion of growth factors. J Trop Pediatr. 1998;44(4):194-8

Moez P, Younan DN. High prevalence of haemoglobin S in the closed Egyptian community of Siwa Oasis. J Clin Pathol. 2016;69(7):632-6.

Hamamy HA, Al-Allawi NA. Epidemiological profile of common haemoglobinopathies in Arab countries. J Community Genet. 2013;4(2):147-67.

WHO. "Sickle-cell anaemia – Report by the Secretariat" (PDF). Archived from the original (PDF) on 4 January 2011. Retrieved 27 November 2010

Adly AA, Ebeid FS. Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt. J Pediatr Hematol Oncol. 2015;37(4):281-4.

Youssry I, Abdel-Salam A, Ismail R, Bou-Fakhredin R, Mohamed Samy R, Ezz El-Deen F, et al. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience. Hemoglobin. 2017;41(4-6):267-73.

Tantawy A, El-Sherif N, Makkeyah S, Eldeen NS, Farghal NBE, Soliman N, et al. Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study. Ann Hematol. 2023;102(2):271-81.

Ebeid FSE. The implementation of automated red blood cell exchange (erythrocytapheresis) as a treatment modality in sickle cell disease patients: Single center experience. Transfus Apher Sci. 2023;62(4):103719.

Kwiatkowski JL, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Alshehri A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-54.

Hamdy M, El-Beshlawy A, Veríssimo MPA, Kanter J, Inusa B, Williams S, et al. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. Pediatr Blood Cancer. 2024;71(1):e30711.

Elalfy MS, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Kanter J, et al. Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. Blood Adv. 2023;7(4):611-9.

Porter JB, El-Alfy M, Viprakasit V, Giraudier S, Chan LL, Lai Y, et al. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. Eur J Haematol. 2016;96(1):19-26.

Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, et al. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7(6):e469-e478.

Aljurf M, Nassar A, Hamidieh AA, Elhaddad A, Hamladji RM, Bazarbachi A, et al. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT). Hematol Oncol Stem Cell Ther. 2015;8(4):167-75.

Ebeid FSE, Aly NH, Shaheen NM, Abdellatif SMA, Okba AAM, Gad NA, et al. Safety and efficacy of L-Glutamine in reducing the frequency of acute complications among patients with sickle cell disease: A randomized controlled study. Ann Hematol. 2024;103(9):3493-506.

Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019;381(6):509-19.

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323-e333.

Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease. Accessed on 25 Sep 2024.

Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, et al. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N. Engl. J. Med. 2016;374(7):625-35.

Heath LE, Heeney MM, Hoppe CC, Adjei S, Agbenyega T, Badr M, et al. Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia. Clin Trials. 2017;14(6):563-71.

De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, et al. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Pediatr Blood Cancer. 2015;62(8):1427-36.

Abdelhalim SM, Murphy JE, Meabed MH, Elberry AA, Gamaleldin MM, Shaalan MS, Hussein RRS. Comparative effectiveness of adding Omega-3 or Vitamin D to standard therapy in preventing and treating episodes of painful crisis in pediatric sickle cell patients. Eur Rev Med Pharmacol Sci. 2022;26(14):5043-52.